Randomized Phase III Trial of SBRT Versus Hypofractionated Radiotherapy for Salvage of Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma After Radical Prostatectomy

Status: Recruiting
Location: See all (6) locations...
Intervention Type: Procedure, Drug, Radiation, Other
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

This phase III trial tests the side effects of stereotactic body radiation therapy (SBRT) compared to hypofractionated radiotherapy for treating patients with prostate adenocarcinoma that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to a limited number of sites (oligometastatic). SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumors cells and have fewer side effects. SBRT may work just as well as hypofractionated radiation therapy at treating patients with biochemically recurrent or oligometastatic prostate cancer, but with a shorter treatment time and possibly fewer side effects.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Healthy Volunteers: f
View:

• Histologically confirmed prostate adenocarcinoma at the time of surgery

• Pathologic stages T2-T3b, Nx or N0-1, M0-1 as staged by the pathology report (American Joint Committee on Cancer \[AJCC\] Criteria 8th edition \[Ed.\])

• PSA post radical prostatectomy ≥ 0.1 and \< 2.0 ng/mL ≤ 90 days prior to enrollment, obtained ≥ 6 weeks after surgery

• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 assessed ≤ 90 days of enrollment

• Patients must sign institutional review board (IRB) approved study specific informed consent

• Patients must complete all required pre-entry tests within the specified time frames

• Patients must be able to start treatment (ADT or radiation) ≤ 120 days of study registration

• Patients must be ≥ 18 years old

• Prostate cancer up to oligometastatic disease, up to 5 sites

Locations
United States
Arizona
Mayo Clinic in Arizona
RECRUITING
Scottsdale
Minnesota
Mayo Clinic Health System in Albert Lea
NOT_YET_RECRUITING
Albert Lea
Mayo Clinic Health System - Mankato
NOT_YET_RECRUITING
Mankato
Mayo Clinic in Rochester
NOT_YET_RECRUITING
Rochester
Wisconsin
Mayo Clinic Health System-Eau Claire Clinic
NOT_YET_RECRUITING
Eau Claire
Mayo Clinic Health System-Franciscan Healthcare
NOT_YET_RECRUITING
La Crosse
Contact Information
Primary
Clinical Trials Referral Office
mayocliniccancerstudies@mayo.edu
855-776-0015
Time Frame
Start Date: 2024-01-22
Estimated Completion Date: 2030-01-22
Participants
Target number of participants: 118
Treatments
Experimental: Group I (SBRT)
Patients undergo SBRT over 15-20 minutes every other day for a total of 5 treatments over 1-2 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive androgen deprivation therapy for up to 18 months, as clinically indicated. Patients undergo PET at screening and treatment failure, and blood sample collection throughout the study. Patients may also undergo MRI as clinically indicated at screening and treatment failure.
Experimental: Group II (Hypofractionated radiation therapy)
Patients undergo hypofractionated radiation therapy over 15-20 minutes once per day for a total of 20 treatments over 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive androgen deprivation therapy for up to 18 months, as clinically indicated. Patients undergo PET at screening and treatment failure, and undergo blood sample collection throughout the study. Patients may also undergo MRI as clinically indicated at screening and treatment failure.
Related Therapeutic Areas
Sponsors
Leads: Mayo Clinic

This content was sourced from clinicaltrials.gov

Similar Clinical Trials